Company intelligence / Profile preview

Ketim Therapeutics

Brisbane, Queensland, Australia

Ownership: Private
Development stage: Preclinical

Overview

Successful pilot study identified an 11-protein signature from blood samples taken at 24 weeks of pregnancy that could predict postpartum depression risk, analyzing over 5,400 proteins using the Olink High Throughput platform[5]

Therapeutic areas: Psychiatry
Modalities: Blood-based biomarkers
Industry: Protein Biomarker Diagnostics

Partnerships

Mater ResearchMater Mother's Hospital (Queensland Family Cohort Study)Australian Genome Research Facility (AGRF)[2][5]

Beyond the preview

Go deeper on Ketim Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ketim Therapeutics.

Explore the full profile